INTERIM FORMULARY UPDATE

The following recommendations, made at the October 13, 2006 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
diphtheria, tetanus,	Boostrix [®] , Adacel [®]	Injection	Immunologic Agents;
acellular pertussis			Toxoids
(Tdap)			
Ophthalmic lubricant	Artificial Tears®	Solution, ophthalmic	Ophthalmics: Lubricants
aripiprazole	Abilify [®]	Tablet, oral	Psychotropic Agents,
		disintegrating: 10mg,	Antipsychotic
		15mg	
*aripiprazole	Abilify [®]	Injection: 9.75 mg/	Psychotropic Agents,
	-	1.3 ml	Antipsychotic

^{*} Approved pending market availability

Product(s) **denied addition** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Acamprosate	Campral®	Tablet, delayed	CNS Agents,
		release: 333 mg	Miscellaneous

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Respiratory Agents and Ophthalmic Agents:

Generic Name	Brand Name	Dosage Form	Classification
budesonide	Pulmicort®	Solution, inhalation:	Respiratory Agents,
		0.25 mg/2 ml,	Steroid
		0.,5 mg/2 ml	
albuterol/ipratropium	Combivent®	Aerosol, inhalation:	Respiratory Agents,
		18 mcg ipratropium/	Miscellaneous
		103 mcg albuterol (14.7	
		g) [200 doses]	
fluticasone/salmeterol	Advair®	Aerosol, inhalation:	Respiratory Agents,
		100 mg	Miscellaneous
		fluticasone/50mg	
		salmeterol, 250 mg	
		fluticasone/50mg	
		salmeterol, 500 mg	
		fluticasone/50mg	
		salmeterol	
ophthalmic irrigation	BSS [®] , Eye Stream [®] ,	Solution, ophthalmic	Ophthalmics;
solution	AK-Rinse®		Miscellaneous
prednisolone		Solution, ophthalmic, as	Ophthalmics;
		sodium phosphate: 1%	Miscellaneous
		Suspension, ophthalmic,	
		as acetate: 0.12%, 1%	

Dosage strength/formulations **recommended to be deleted** from the DADS/DSHS Drug Formulary based on the Sectional Reviews for Immunological Agents, Intravenous Solutions and Additives, and Nutritional Agents:

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
None			

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Agents for Review:

Generic Name	Brand Name	Dosage Form	Classification
levetiracetam	Keppra®	1000mg	Anticonvulsants,
			Miscellaneous
brompheniramine/pseudo		Tablet, SR 6mg/120mg	Respiratory Agents,
ephedrine		Liquid, oral: 15mg/1mg per 5ml,	Cough & Cold
		12mg/1mg per 5ml	Preparations
aminophylline		Tablet, 200mg	Respiratory Agents,
			Bronchodilators
beclomethasone	Qvar [®]	Spray, Nasal: 40mcg/actuation	Respiratory Agents,
			Steroids
guaifenesin/dextromethor		Tablet, SR: 600mg/30mg	Respiratory Agents,
phan		Liquid, Oral: 100mg/15mg per	Cough & Cold
		5ml, 66.7mg/6.7mg per 5ml	Preparations

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Agents for Review: continued

Generic Name	Brand Name	Dosage Form	Classification
loratadine	Claritin®	Liquid Oral: 5mg/5ml	Respiratory Agents,
			Cough & Cold
			Preparations
montelukast	Singular®	Tablet, Chewable: 5mg	Respiratory Agents,
			Miscellaneous
theophylline		Tablet, time release tablet SR (12	Respiratory Agents,
		hour): 100mg, 200mg, 300mg	Bronchodilators

Previously, the Executive Formulary Committee requested input from the field regarding the following drugs proposed for deletion from the DADS/DSHS Drug Formulary. Based on the field's response, the following drugs are deleted from the Drug Formulary.

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
poliovirus vaccine,	Ipol [®]	Injection, single dose	None
inactivated			
rubella Virus	Meruvax II®	Injection, single dose	Measles, Mumps and Rubella
vaccine Live			Vaccine, Live (MMR II®)
dextran	Gentran [®] ,	High molecular weight: 6%	None
	LMD [®] ,	Dextran 75 in D4W, 6%	
	Macrodex [®] ,	Dextran 75 in NX, 6%	
	Rheomacrodex®	Dextran 70 in NS	
		Low molecular weight: 10%	
		Dextran 40 in D5W,	
		10 % Dextran in NS	

Other recommendations:

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

- Add Vospire [®] ER as a trade name for albuterol
 Remove Vanceril [®] as a trade name for beclomethasone
- 3. Add Cromolyn to Decongestant/Antiallergy section

Approved:

Pharmacy Services Director San Antonio State Hospital

ann L. Richards